Skip to main content

Table 1 Claims-based algorithm for accessing effectiveness after one year of follow-up in patients with rheumatoid arthritis

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Criteria Description of criteria
Criterion 1
High adherence
Adherence to therapy was defined as follows:
• For medications with pharmacy claims only: MPR ≥ 80%a
• For medications with procedure claims only:
 Etanercept: ≥ 48 procedures
 Adalimumab: ≥ 22 procedures
 Certolizumab: ≥ 22 procedures
 Golimumab: ≥ 11 procedures
 Infliximab: ≥ 8 procedures
 Rituximab: ≥ 4 procedures
 Abatacept: ≥ 11 procedures
 Tocilizumab: ≥ 11 procedures
Criterion 2
No prescription or procedure of a new biologic or tofacitinib during follow-up
No prescription or procedure of a new biologic or tofacitinib during follow-up
Criterion 3
No DMARD switch or addition
No prescription of a new DMARD between months 4 and 12 of follow-up
Criterion 4
No increase in dose or frequency of index drug
No increase in dose or frequency of index drug
• For medications with pharmacy claims only: ≥ 10% of the daily dose at any time during follow-up compared with the daily dose at cohort entry
• For medications with procedure claims only:
 Adalimumab: > 25 procedures
 Certolizumab: > 25 procedures
 Golimumab: > 12 procedures
 Infliximab: > 9 procedures
 Rituximab: > 5 procedures
 Abatacept: > 13 procedures
 Tocilizumab: > 12 procedures
 Etanercept: > 55 procedures
Criterion 5
No more than one procedure for glucocorticoid joint injection between months 4 and 12 of follow-up
No more than one procedure for glucocorticoid joint injection between months 4 and 12 of follow-up
Criterion 6
No new/increased oral glucocorticoid dose
No increase in dose of oral glucocorticoid
• For patients who received no prescriptions for oral glucocorticoids 6 months prior to cohort entry: > 30 days of cumulative oral glucocorticoid between months 4 and 12 of follow-up
• For patients who received prescriptions for oral glucocorticoids 6 months prior to cohort entry: cumulative dose between months 7 and 12 of follow-up ≥ 120% cumulative dose 6 months prior to cohort entry
  1. MPR Medication possession ratio, DMARD Disease-modifying antirheumatic drug
  2. Adapted from Curtis et al., 2011 [15]
  3. aA patient was considered highly adherent if the total days’ supply of drug divided by the total days of follow-up was ≥ 80%